IRIS
BUGATTI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.650
AS - Asia 3.042
EU - Europa 2.098
SA - Sud America 454
Continente sconosciuto - Info sul continente non disponibili 366
AF - Africa 110
OC - Oceania 7
Totale 9.727
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.538
CN - Cina 1.160
SG - Singapore 737
IE - Irlanda 474
VN - Vietnam 424
HK - Hong Kong 365
BR - Brasile 331
RU - Federazione Russa 302
DE - Germania 270
FI - Finlandia 241
IT - Italia 222
UA - Ucraina 134
FR - Francia 131
GB - Regno Unito 100
SE - Svezia 91
IN - India 74
ZA - Sudafrica 60
CA - Canada 58
BD - Bangladesh 53
AR - Argentina 34
AE - Emirati Arabi Uniti 23
JP - Giappone 23
MX - Messico 23
CO - Colombia 22
EC - Ecuador 22
TR - Turchia 21
VE - Venezuela 21
ID - Indonesia 20
ES - Italia 19
BE - Belgio 18
PK - Pakistan 18
IQ - Iraq 16
MY - Malesia 15
IR - Iran 14
NL - Olanda 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
PL - Polonia 13
AT - Austria 11
PH - Filippine 11
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
UZ - Uzbekistan 9
PE - Perù 8
CL - Cile 7
JM - Giamaica 7
KE - Kenya 7
IL - Israele 6
TH - Thailandia 6
AL - Albania 5
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
CR - Costa Rica 4
GR - Grecia 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
CU - Cuba 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
UY - Uruguay 3
CY - Cipro 2
EU - Europa 2
HU - Ungheria 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
BB - Barbados 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EE - Estonia 1
GT - Guatemala 1
HR - Croazia 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MQ - Martinica 1
Totale 9.354
Salva come PNG Salva come JPEG
Città #
Dublin 467
San Jose 443
Chandler 415
Singapore 397
Hong Kong 351
Ashburn 333
Dallas 320
Beijing 251
Jacksonville 195
Nanjing 195
Ho Chi Minh City 138
Boardman 124
Helsinki 113
Hanoi 106
New York 104
Munich 102
Lauterbourg 101
Los Angeles 91
Princeton 81
Lawrence 75
Wilmington 75
Nanchang 68
Ann Arbor 64
Council Bluffs 60
Shenyang 59
Shanghai 57
Medford 51
Hebei 50
Changsha 49
Johannesburg 49
Moscow 49
Milan 47
Da Nang 45
Santa Clara 44
Buffalo 42
Redondo Beach 42
Turku 42
Jiaxing 36
Pavia 30
São Paulo 30
Hangzhou 25
Montreal 25
Orem 24
Tianjin 21
Tokyo 20
Dubai 19
Piscataway 19
Brussels 18
London 18
Seattle 18
The Dalles 18
Woodbridge 18
Chennai 17
Denver 17
Rio de Janeiro 17
Toronto 17
Brooklyn 15
Frankfurt am Main 14
Columbus 13
Haiphong 12
Stockholm 12
Tabriz 12
Atlanta 11
Fairfield 11
Falkenstein 11
Manchester 11
Norwalk 11
Nuremberg 11
Warsaw 11
Poplar 10
Chicago 9
Guangzhou 9
Houston 9
Mexico City 9
Quito 9
Baghdad 8
Belo Horizonte 8
Medellín 8
Mumbai 8
Verona 8
Washington 8
Zhengzhou 8
Amsterdam 7
Berlin 7
Phoenix 7
Phủ Lý 7
Bari 6
Biên Hòa 6
Brno 6
Bến Tre 6
Dhaka 6
Elk Grove Village 6
Guayaquil 6
Jeddah 6
Kuala Lumpur 6
Nairobi 6
Newark 6
Philadelphia 6
Porto Alegre 6
San Francisco 6
Totale 6.080
Salva come PNG Salva come JPEG
Nome #
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 152
B cells in rheumatoid arthritis. 151
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 145
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 144
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 141
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 139
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 138
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 130
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 124
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 122
B cells in rheumatoid arthritis. 121
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 120
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 119
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 118
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 116
B cell autoimmunity and bone damage in rheumatoid arthritis 114
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 113
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 112
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 111
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 110
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 109
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 108
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 108
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 105
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 103
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 101
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 101
Adult-onset Still's disease with elderly onset, results from a multicentre study 100
null 97
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 96
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 94
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 94
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 94
Long term treatment of rheumatoid arthritis with rituximab 93
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 93
Established rheumatoid arthritis. The pathogenic aspects. 93
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 93
Long term treatment of rheumatoid arthritis with rituximab. 92
Insights Into the Concept of Rheumatoid Arthritis Flare 92
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 91
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 90
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 90
Seronegative autoimmune diseases: A challenging diagnosis 89
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 89
Nuovi aspetti patogenetici dell’artrite reumatoide 89
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 88
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 88
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 88
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 87
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 87
Anti-neutrophil cytoplasmic antibodies (ANCA) 85
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 85
Synovial tissue heterogeneity and peripheral blood biomarkers 85
Early treatment in early undifferentiated arthritis 84
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 83
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 83
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 83
High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis 82
Tumor necrosis factor-α inhibitor-related autoimmune disorders 82
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 82
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 81
Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat 80
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study 80
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 80
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 80
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 80
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 79
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 79
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist 77
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 76
Differences and similarities in rheumatology specialty training programmes across European countries 76
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 75
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 74
Clinical Applications of Synovial Biopsy. 74
Rheumatology training experience across Europe: Analysis of core competences 73
Tender joints in early autoantibody-negative rheumatoid arthritis: Should they be included in the scoring of joint involvement of the 2010 ACR/EULAR classification criteria? 72
Long-term safety of abatacept in patients with rheumatoid arthritis 71
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 71
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 71
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 71
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 70
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 70
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 69
Seronegative rheumatoid arthritis: one year in review 2023 68
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 68
La linfoneogenesi 68
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 68
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 68
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 67
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 66
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 65
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 65
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 64
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 64
Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice 63
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 62
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs 61
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 57
Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases 55
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective 54
Totale 9.028
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.653
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022358 0 3 12 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/20251.775 43 111 24 24 21 110 124 101 468 94 236 419
2025/20264.084 307 273 458 374 461 147 862 228 325 279 203 167
2026/2027115 70 45 0 0 0 0 0 0 0 0 0 0
Totale 9.727